Literature DB >> 19817542

A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme.

Kaisorn Chaichana1, Scott Parker, Alessandro Olivi, Alfredo Quiñones-Hinojosa.   

Abstract

OBJECT: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults. Although the average survival is approximately 12 months, individual survival is heterogeneous. The ability to predict short- and long-term survivors is limited. Therefore, the aims of this study were to ascertain preoperative risk factors associated with survival, develop a preoperative prognostic grading system, and evaluate the utility of this grading system in predicting survival for patients undergoing resection of a primary intracranial GBM.
METHODS: Cases involving adult patients who underwent surgery for an intracranial primary (de novo) GBM between 1997 and 2007 at The Johns Hopkins Hospital, an academic tertiary-care institution, were retrospectively reviewed. Multivariate proportional hazards regression analysis was used to identify preoperative factors associated with survival, after controlling for extent of resection and adjuvant therapies. The identified associations with survival were then used to develop a grading system based on preoperative variables. Survival as a function of time was plotted using the Kaplan-Meier method, and survival rates were compared using Log-rank analysis. Associations with p < 0.05 were considered statistically significant.
RESULTS: Of the 393 patients in this study, 310 (79%) had died as of most recent follow-up (median time from surgery to death 11.9 months). The preoperative factors, independent of extent of resection and adjuvant therapies (carmustine wafers, temozolomide, and radiation), found to be negatively associated with survival were: age > 60 years (p < 0.0001), Karnofsky performance status score < or = 80 (p < 0.0001), motor deficit (p = 0.02), language deficit (p = 0.001), and periventricular tumor location (p = 0.04). Patients possessing 0-1, 2, 3, and 4-5 of these variables were assigned a preoperative grade of 1, 2, 3, and 4, respectively. Patients with a preoperative grade of 1, 2, 3, and 4 had a median survival of 16.6, 10.2, 6.8, and 6.1 months, respectively.
CONCLUSIONS: The present study found that older age, poor performance status, motor deficit, language deficit, and periventricular tumor location independently predicted poorer survival in patients undergoing GBM resection. A grading system based on these factors was able to identify 4 distinct groups of patients with different survival rates. This grading system, based only on preoperative variables, may provide patients and physicians with prognostic information that may guide medical and surgical therapy before any intervention is pursued.

Entities:  

Mesh:

Year:  2010        PMID: 19817542     DOI: 10.3171/2009.9.JNS09805

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  51 in total

1.  Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  J Neurooncol       Date:  2013-09-13       Impact factor: 4.130

2.  Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.

Authors:  Gabriel Charest; Léon Sanche; David Fortin; David Mathieu; Benoit Paquette
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

3.  The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.

Authors:  Kaisorn L Chaichana; Hasan Zaidi; Courtney Pendleton; Matthew J McGirt; Rachel Grossman; Jon D Weingart; Alessandro Olivi; Alfredo Quiñones-Hinojosa; Henry Brem
Journal:  Neurol Res       Date:  2011-09       Impact factor: 2.448

4.  Patterns of care and survival for glioblastoma patients in the Veterans population.

Authors:  Robert T Arrigo; Maxwell Boakye; Stephen L Skirboll
Journal:  J Neurooncol       Date:  2011-09-01       Impact factor: 4.130

5.  Can lateral ventricle contact predict the ontogeny and prognosis of glioblastoma?

Authors:  Sheng Han; Xiang Li; Bo Qiu; Tao Jiang; Anhua Wu
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

6.  Motivating the additional use of external validity: examining transportability in a model of glioblastoma multiforme.

Authors:  Kyle W Singleton; William Speier; Alex A T Bui; William Hsu
Journal:  AMIA Annu Symp Proc       Date:  2014-11-14

7.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

8.  Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.

Authors:  Nazia F Jafri; Jennifer L Clarke; Vivian Weinberg; Igor J Barani; Soonmee Cha
Journal:  Neuro Oncol       Date:  2012-10-24       Impact factor: 12.300

9.  Time trends in glioblastoma multiforme survival: the role of temozolomide.

Authors:  Robert Dubrow; Amy S Darefsky; Daniel I Jacobs; Lesley S Park; Michal G Rose; Maxwell S H Laurans; Joseph T King
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

10.  Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome.

Authors:  Kuntal Kanti Das; Anant Mehrotra; Anup P Nair; Shaleen Kumar; Arun K Srivastava; Rabi N Sahu; Raj Kumar
Journal:  Childs Nerv Syst       Date:  2012-08-19       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.